TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26562660

Group type: EXPERIMENTAL
Intervention: Physiotherapy/leaflet
Number of subjects: 59

Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 59
Study: 24070911

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 83
Study: 21222131

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (600 mg EPA and 400 mg DHA per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (600 mg EPA and 400 mg DHA per day) + antioxidants (30 mg vitamin E, 60 mg vitamin C, 6 mg β-carotene)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 36
Study: 18987031

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study: 17854246

Group type: EXPERIMENTAL
Intervention: Risperidone long‐acting injection (25 mg, 37.5 mg, or 50 mg every 2 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral risperidone (4 mg/day or less, 4-6 mg/day, or more than 6 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Risperidone long‐acting injection (25 mg or 37.5 mg every 2 weeks)
Number of subjects: 50
Study: 15701857

Group type: EXPERIMENTAL
Intervention: PemOx (pemetrexed 500 mg/m² plus oxaliplatin 120 mg/m²)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PemCb (pemetrexed plus carboplatin AUC6)
Number of subjects: 80
Study: 11892854

Group type: EXPERIMENTAL
Intervention: Combination of a brochure and videotape
Number of subjects: 149

Group type: COMPARATOR
Intervention: Brochure alone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Parents with more accurate expectations
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Preparation procedures
Number of subjects: 149
Study: 9535247

Group type: EXPERIMENTAL
Intervention: 10 microg DTPwHB vaccine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5 microg DTPwHB vaccine
Number of subjects: 120
Study: 7805711

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg once a day (n = 10)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Permixon 80 mg x 2 twice a day (n = 11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo once a day (n = 11)
Number of subjects: 32
Study: 2683535

Group type: EXPERIMENTAL
Intervention: 1-day treatment with metronidazole and ampicillin
Number of subjects: 62

Group type: COMPARATOR
Intervention: 4-day treatment with metronidazole and ampicillin
Number of subjects: 62
Study: 30980691

Group type: EXPERIMENTAL
Intervention: Wearable tracker for 12 weeks, two group sessions, and a support phone call
Number of subjects: 68

Group type: COMPARATOR
Intervention: Print materials describing physical activity guidelines
Number of subjects: 68
Study: 28776894

Group type: EXPERIMENTAL
Intervention: 75 μg/kg initial dose of activated eptacog beta (rhFVIIa)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 225 μg/kg initial dose of activated eptacog beta (rhFVIIa)
Number of subjects: 27
Study: 25015548

Group type: EXPERIMENTAL
Intervention: Nasal insufflation (NI) therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 10
Study: 23354313

Group type: EXPERIMENTAL
Intervention: Fit Body and Soul (FBAS)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Health-education comparison program
Number of subjects: 604
Study: 22128654

Group type: EXPERIMENTAL
Intervention: Group prenatal care (GPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual prenatal care
Number of subjects: 0
Study: 19339401

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional diabetes diet
Number of subjects: 99
Study: 15562200

Group type: EXPERIMENTAL
Intervention: LAF237 (50 mg once daily, n=56)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: LAF237 (50 mg once daily, n=42)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (n=51)
Number of subjects: 107
Study: 10411436

Group type: EXPERIMENTAL
Intervention: Colonic pouch
Number of subjects: 59

Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 59
Study: 7586947

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ciprofloxacin alone (without probenecid)
Number of subjects: 12
Study: 2274625

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6991095

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (IV 5‐FU) alone, 15 mg/kg/week
Number of subjects: 121

Group type: COMPARATOR
Intervention: Combination therapy: cyclophosphamide (15 mg/kg/week IV on day 1) plus 5-fluorouracil (15 mg/kg/week IV during weeks 2‐5)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both arms (5-FU alone and combination therapy)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients with pretreatment WBC greater than 12,000/mm3
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pretreatment lymphocyte count
Number of subjects: 121
Study: 31791947

Group type: EXPERIMENTAL
Intervention: GSK656
Number of subjects: 187
Study: 29016381

Group type: EXPERIMENTAL
Intervention: Closed tunnel endoscopic vein harvesting (n=100)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Open tunnel endoscopic vein harvesting (n=100)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Open vein harvesting (n=101)
Number of subjects: 301
Study: 25436448

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up (ABC) intervention (n=54)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control intervention (n=61)
Number of subjects: 115
Study: 23317441

Group type: EXPERIMENTAL
Intervention: Three-midline-ports approach (Group 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: French technique with three ports (Group 1)
Number of subjects: 100
Study: 21553966

Group type: EXPERIMENTAL
Intervention: Self‐affirming questionnaire
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Self‐affirming implementation intention
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control questionnaire
Number of subjects: 278
Study: 19184409

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17762738

Group type: EXPERIMENTAL
Intervention: Embolization treatment for DAVFs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (patients with unruptured intracranial aneurysms)
Number of subjects: 18
Study: 15479137

Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 11
Study: 11700964

Group type: COMPARATOR
Intervention: Normal cornea examination using confocal microscope
Number of subjects: 120
Study: 9512283

Group type: EXPERIMENTAL
Intervention: 4 L PEG‐ELS
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2 L PEG‐ELS plus 296 mL magnesium citrate 1 hour prior
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2 L PEG‐ELS plus bisacodyl 20 mg
Number of subjects: 150
Study: 7999653

Group type: EXPERIMENTAL
Intervention: L + F group (n = 27) - 38 mL of 1.5% lidocaine with 1/200,000 epinephrine and 100 micrograms of fentanyl
Number of subjects: 53

Group type: COMPARATOR
Intervention: L + S group (n = 26) - 38 mL of 1.5% lidocaine with 1:200,000 epinephrine and 2 mL of normal saline
Number of subjects: 53
Study: 31650255

Group type: EXPERIMENTAL
Intervention: Computerised cognitive training (CCT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Specific CCT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CCT on SCD
Number of subjects: 12
Study: 29945780

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg + 10 g Cr monohydrate (n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (atorvastatin 80 mg + PL, n = 9)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 27296201

Group type: EXPERIMENTAL
Intervention: CoreValve transcatheter aortic valve replacement
Number of subjects: 156
Study: 25066668

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study: 23739042

Group type: EXPERIMENTAL
Intervention: PCSO-524™
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fish oil
Number of subjects: 0
Study: 20613461

Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 515
Study: 19205870

Group type: EXPERIMENTAL
Intervention: HRV biofeedback and breathing retraining
Number of subjects: 29

Group type: COMPARATOR
Intervention: Quasi‐false alpha‐theta biofeedback
Number of subjects: 29
Study: 17090333

Group type: EXPERIMENTAL
Intervention: Guided imagery with progressive muscle relaxation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Breathing exercises alone
Number of subjects: 22
Study: 15360809

Group type: EXPERIMENTAL
Intervention: FastTrack e-mail intervention
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 276
Study: 11230288

Group type: EXPERIMENTAL
Intervention: Endothelium-dependent vasodilatation with acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg. 100 mL(‐1). min(‐1))
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Endothelium-independent vasodilatation with sodium nitroprusside (1, 2, and 4 microg. 100 mL(‐1). min(‐1))
Number of subjects: 142
Study: 9225641

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive with 20 micrograms ethinyl estradiol (EE)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Combined oral contraceptive with 30 micrograms ethinyl estradiol (EE)
Number of subjects: 5000
Study: 7968419

Group type: EXPERIMENTAL
Intervention: Isokinetic (IK) strength training program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonisokinetic (NIK) strength training program
Number of subjects: 18
Study: 2889391

Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerine 0.75 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo solution of saline (Control)
Number of subjects: 40
Study: 29704183

Group type: EXPERIMENTAL
Intervention: Centralized collaborative care model
Number of subjects: 666

Group type: COMPARATOR
Intervention: Existing collaborative care model
Number of subjects: 666
Study: 27852230

Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg IV preoperatively
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 24126567

Group type: EXPERIMENTAL
Intervention: ACT-280778 single doses of 2, 5, 15, or 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-280778 single dose of 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-280778 once-daily doses of 5 or 15 mg for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-280778
Number of subjects: 0
Study: 23965227

Group type: EXPERIMENTAL
Intervention: Decision aids (DAs) for coronary prevention and diabetes medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-clinic approach for recruitment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working closely with the practice
Number of subjects: 0
Study: 20627902

Group type: EXPERIMENTAL
Intervention: Stemless poly‐L/D‐lactide copolymer 96 : 4 (PLDLA) implant
Number of subjects: 52

Group type: COMPARATOR
Intervention: Swanson silicone implant
Number of subjects: 52
Study: 18311686

Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15843118

Group type: EXPERIMENTAL
Intervention: Healthy Relationships intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: health maintenance control condition
Number of subjects: 81
Study: 12750879

Group type: COMPARATOR
Intervention: Pamidronate alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pamidronate and fluoride
Number of subjects: 40
Study: 10531155

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 microg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8905360

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.2 mg incrementally after procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study: 2069240

Group type: EXPERIMENTAL
Intervention: High frequency positive pressure ventilation (HFPPV group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: One-lung ventilation (OLV group)
Number of subjects: 42
Study: 6311692

Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg bd
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: cimetidine 300 mg nocte
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg bd
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg nocte
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: twice daily ranitidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: night time ranitidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: twice daily cimetidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: night time cimetidine
Number of subjects: 12
Study: 30582753

Group type: EXPERIMENTAL
Intervention: 800 μg of sublingual misoprostol
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 28673310

Group type: EXPERIMENTAL
Intervention: Enhanced content feedback intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced follow-on support feedback intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current practice (control group)
Number of subjects: 0
Study: 27237936

Group type: EXPERIMENTAL
Intervention: HTS training with electrical stimulation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 16
Study: 25222001

Group type: EXPERIMENTAL
Intervention: Multilayer amniotic membrane transplantation (AMT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lamellar corneal transplantation (LCT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lamellar scleral transplantation (LST)
Number of subjects: 26
Study: 21971319

Group type: EXPERIMENTAL
Intervention: Milrinone, 0.5 µg/kg/min during hypothermic cardiopulmonary bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 19651277

Group type: COMPARATOR
Intervention: Sitting position HCVR in patients with tetraplegia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sitting position HCVR in healthy controls
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Supine FVC in patients with tetraplegia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Supine HCVR in patients with tetraplegia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mean supine blood pressure in patients with tetraplegia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mean erect blood pressure in patients with tetraplegia
Number of subjects: 19
Study: 17469236

Group type: EXPERIMENTAL
Intervention: HMB (3 g/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 14981122

Group type: EXPERIMENTAL
Intervention: DCMs stored in artificial saliva for 250 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: DCMs stored in artificial saliva for 24 hours and 90 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: DCMs stored with proteolytic enzyme inhibitors or mineral oil
Number of subjects: 0
Study: 11356653

Group type: EXPERIMENTAL
Intervention: Prenatal cocaine exposure (PCE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no prenatal cocaine exposure)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups during active sleep
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups during quiet sleep
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 9408555

Group type: EXPERIMENTAL
Intervention: Dexedrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8195581

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study: 3793849

Group type: COMPARATOR
Intervention: Placebo membrane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5 mg testosterone membrane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 mg testosterone membrane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 15 mg testosterone membrane
Number of subjects: 6
Study: 30559106

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 27775485

Group type: EXPERIMENTAL
Intervention: Cognitively complex card game (trained group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Computerized version of a simple dice-game of chance (control group)
Number of subjects: 29
Study: 26100557

Group type: EXPERIMENTAL
Intervention: 0.1% scFOS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25% scFOS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% scFOS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (0% scFOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: scFOS (various concentrations)
Number of subjects: 0
Study: 24952855

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-guided antiplatelet therapy (clopidogrel for *1/*1 patients, ticagrelor or prasugrel for *2 or *3 allele carriers)
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Routine treatment with ticagrelor or prasugrel
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-guided antiplatelet therapy
Number of subjects: 2700
Study: 22540993

Group type: EXPERIMENTAL
Intervention: GnRH agonist with a long-term protocol
Number of subjects: 64

Group type: COMPARATOR
Intervention: GnRH antagonist with a multi-dose protocol
Number of subjects: 64
Study: 19481812

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (40 mg in 1 ml)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 163
Study: 17539869

Group type: EXPERIMENTAL
Intervention: Carbohydrate-supplemented breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat-supplemented breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic breakfast
Number of subjects: 0
Study: 15334625

Group type: EXPERIMENTAL
Intervention: 1000 mg metformin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1500 mg metformin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2000 mg metformin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2500 mg metformin
Number of subjects: 24
Study: 11489571

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (40 eyes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasound (US) (25 eyes)
Number of subjects: 50
Study: 9535416

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 7632462

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 28
Study: 2506217

Group type: EXPERIMENTAL
Intervention: 50 micrograms octreotide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 micrograms octreotide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 793550

Group type: EXPERIMENTAL
Intervention: Pericardium closed with interrupted silk
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pericardium left open
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 31586198

Group type: EXPERIMENTAL
Intervention: Common surgical method (1a) with soft palate closure at 3-4 months and hard palate closure at 12 months
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Common surgical method (2a) with soft palate closure at 3-4 months and hard palate closure at 12 months
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Common surgical method (3a) with soft palate closure at 3-4 months and hard palate closure at 12 months
Number of subjects: 429

Group type: COMPARATOR
Intervention: Delayed hard palate closure (1b)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Simultaneous closure of both hard and soft palate at 1 year (2c)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Hard palate closure together with lip closure at 3 months and soft palate closure at 1 year (3d)
Number of subjects: 429
Study: 31645286

Group type: EXPERIMENTAL
Intervention: Light general anaesthesia (BIS target 50)
Number of subjects: 6644

Group type: COMPARATOR
Intervention: Deep general anaesthesia (BIS target 35)
Number of subjects: 6644
Study: 28875295

Group type: EXPERIMENTAL
Intervention: SWL
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: RIRS
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: PCNL
Number of subjects: 582
Study: 26062658

Group type: EXPERIMENTAL
Intervention: Physical trauma
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Crime-related trauma
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PTSD symptom severity
Number of subjects: 88
Study: 23856771

Group type: EXPERIMENTAL
Intervention: GSK2336805 (150 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21286910

Group type: EXPERIMENTAL
Intervention: Resection suspension arthroplasty according to Epping
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Trapezectomy with interposition of pyrocarbon spacers
Number of subjects: 84
Study: 19150702

Group type: EXPERIMENTAL
Intervention: Step-up treatment with antacid, H2-receptor antagonist, and proton pump inhibitor (n=341)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Step-down treatment with proton pump inhibitor, H2-receptor antagonist, and antacid (n=323)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Step-up treatment (n=341)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Step-down treatment (n=323)
Number of subjects: 664
Study: 17199535

Group type: EXPERIMENTAL
Intervention: SRP with the periodontal endoscope
Number of subjects: 15

Group type: COMPARATOR
Intervention: SRP without the periodontal endoscope (control)
Number of subjects: 15
Study: 15119993

Group type: EXPERIMENTAL
Intervention: 750 mg levofloxacin for 5 days
Number of subjects: 123

Group type: COMPARATOR
Intervention: 500 mg levofloxacin for 10 days
Number of subjects: 123